Compare · AZN vs IMNM
AZN vs IMNM
Side-by-side comparison of AstraZeneca PLC (AZN) and Immunome Inc. (IMNM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and IMNM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 125.9x IMNM ($2.05B).
- AZN has been more active in the news (18 items in the past 4 weeks vs 6 for IMNM).
- AZN has more recent analyst coverage (25 ratings vs 16 for IMNM).
- Company
- AstraZeneca PLC
- Immunome Inc.
- Price
- $165.42-0.74%
- $16.47-5.40%
- Market cap
- $258.47B
- $2.05B
- 1M return
- -
- -31.20%
- 1Y return
- -
- +4.84%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 18
- 6
- Recent ratings
- 25
- 16
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest IMNM
- William Blair initiated coverage on Immunome
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- Stifel initiated coverage on Immunome with a new price target
- Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
- Alliance Global Partners initiated coverage on Immunome with a new price target
- Chief Scientific Officer Higgins Jack exercised 18,000 shares at a strike of $1.35, sold $334,224 worth of shares (13,200 units at $25.32) as part of a pre-agreed trading plan and gifted 8,800 shares, decreasing direct ownership by 7% to 56,250 units (SEC Form 4)
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Director Barchas Isaac sold $2,198,910 worth of shares (83,464 units at $26.35) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 92,211 units (SEC Form 4)